Section 503A permits compounding of drug products as customized therapies for identified individual patients whose medical needs cannot be met by commercially available drug products. 503B compounding , on the other hand, is performed at outsourcing facilities, which are subject to stricter FDA oversight, including cGMP requirements, a requirement to register with FDA, periodic FDA inspections and an obligation to submit adverse event reports and other product-specific information to FDA
7 In patients with severe pain from thrombosed hemorrhoids, excision or incision and evacuation of the thrombus within 72 hours of symptom onset provide more rapid pain relief than conservative treatment
(2013) and Tudor et al
13,000 per month for the 2.5 mg starting dose
Notably, the infiltration and activation of inflammatory cells (neutrophils, macrophages) during reperfusion introduce a substantial source of ROS via their highly active phagocytic NOX (NOX2) system (Li et al., 2025)